Chinese vaccine shields against hepatitis E - Lancet

Aug 23, 2010

A prototype vaccine devised and tested in China has proven 100-percent effective in preventing hepatitis E, a disease that is widespread in the developing world and can be fatal, investigators reported in The Lancet on Monday.

The formula, tested on 100,000 volunteers in Jiangsu provinces, was completely effective after three doses and side effects were "few and mild", they said.

The hepatitis E virus, often transmitted by faecal contamination of water supplies, causes liver inflammation, whose symptoms are jaundice, fever and vomiting. It was only recognised as a distinct disease 30 years ago.

Around a third of the world's population have been infected by the virus, according to figures cited in the study.

Mortality from the disease is low, but people with and pregnant mothers and their foetuses are badly at risk.

The Jiangsu trial is the third and final phase of the process to assess a new for safety and effectiveness.

The trialled formula, codenamed HEV 239, is a recombinant vaccine, meaning that it includes a protein from the virus designed to stimulate the body's immune defences.

It was administered to 48,000 healthy adults aged 16-65, while an identical group of counterparts received a placebo. Three doses were issued over six months, and the volunteers were then monitored for a year.

Fifteen fell ill with hepatitis E in the placebo group, but there were no cases in the vaccine group.

Another piece of good news is that the vaccine was also fully effective among those who had received only two doses.

"During a outbreak, or for travellers to an endemic area, protection can be quickly obtained by two vaccine doses given within one month," said the study, headed by Nin-Shao Xia, of the Institute of Diagnostic and Vaccine Development in in Xiamen.

Explore further: Flu vaccine may hold key to preventing heart disease

add to favorites email to friend print save as pdf

Related Stories

Possible hepatitis C vaccine

Sep 05, 2007

Hepatitis C Virus (HCV) infects up to 500,000 people in the UK alone, many of the infections going undiagnosed. It is the single biggest cause of people requiring a liver transplant in Britain. Now, in a collaborative effort ...

Vaccine shows promise in preventing mono

Dec 10, 2007

A new study suggests that a vaccine targeting Epstein-Barr virus (EBV) may prevent infectious mononucleosis, commonly known as “mono” or “glandular fever.” The study is published in the December 15 issue of The Jo ...

Vaccine against CMV shows promise in clinical trial

Mar 18, 2009

A new vaccine has the potential to be the first to prevent maternal and congenital cytomegalovirus (CMV) infection, according to a University of Alabama at Birmingham (UAB) study published in the March 19 edition of the New En ...

Recommended for you

Seaweed menace may yield new medicines

1 hour ago

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Modernmystic
1 / 5 (1) Aug 23, 2010
I didn't even know there was a Hep E...